Skip to main content

Table 1 Patient data before and after Glargine therapy

From: Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine

 

Age (years)

Lumacaftor Ivacaftor

BMI

z-score

FEV1 (%)

Annual number of pulmonary exacerbations

Annual number of pulmonary exacerbations treated by intravenous antibiotics

2016 (before Glargine therapy)

13.1

NO

−1.58

90.4%

7

4

2017 (1 year of Glargine therapy)

14.5

NO

−1.54

91%

4

2

2018 (2 years of Glargine therapy)

15.7

YES

−1.47

75%

2

0

2019 (3 years of Glargine therapy)

16.3

YES

−1.78

74%

3

0

2020 (COVID-19 pandemic lockdown)

17.0

YES

−2.47

68%

4

0

2020 (November)

17.6

YES

−1.58

71%

4

0